medical devices Archives

Subscribe to the medical devices RSS feed.

BSG Team Ventures completes Bay Area Medical Devices CEO search for Novel Suturing Technology out of Stanford University

BSG  Team Ventures is pleased to announce the successful completion of CEO search for Zipline Medical.

BSG recruited John Tighe, former CEO of PEAK Surgical, to join Zipline Founder & Chief Technology Officer Dr. Amir Belson.

Prior to being recruited to ZipLine Medical, Mr. Tighe was a Director and President and CEO of PEAK Surgical, joining the company as its first employee in June 2006. In July 2011, he negotiated the acquisition of PEAK Surgical by Medtronic. Mr. Tighe was responsible for establishing clinical development and sales of PEAK’s novel radio frequency technology in a variety of surgical specialties, including General Surgery, ENT, Orthopedics, and Plastic Surgery. Prior to joining PEAK, he served as Senior Vice President and General Manager at Arthrocare Corp., where he managed the company’s three business units, comprised of Sports Medicine, ENT, and Spine. During his time at the company, Arthrocare was one of the fastest-growing publicly traded medical device companies. Mr. Tighe is a member of the Community Advisory Board of El Camino Hospital of Los Gatos (CA), and earned a bachelor’s degree in Civil Engineering at the University of Maryland.

ZipLine Medical (www.ziplinemedical.com), headquartered in Campbell, Calif., is an emerging medical device company that has developed a platform technology — PRELOCTM (Pre-placement RE- aligning Low-tension Closure) — for noninvasive surgical skin closure via a simple, easy-to-learn and easy-to-use device. Because skin-closure is a common denominator of almost all surgeries, ZipLine’s PRELOC platform for the pre-placement, reapproximation and low-tension realignment of skin tissue has broad applicability across numerous medical specialties. There is an existing $4.2 billion worldwide market opportunity covering most surgical procedures involving skin incision. ZipLine’s initial target applications include: C-section, laparotomy, pacemaker/ICD implant, laparoscopic port, orthopedic, and excisional skin biopsy closure.

For more information see, Zipline press release at

http://www.ziplinemedical.com/press_release/zipline-medical-announces-appointment-of-john-r-tighe-as-ceo/

BSG Team Ventures appoints Todd Hand Managing Director of new sister brand, TalentBench

BOSTON, MA, August 00, 2012– BSGTeam Ventures (BSG) today announced the appointment of Todd Hand (www.talentbench.net/company/principals/) as Managing Director of TalentBench (www.talentbench.net), a division of BSG. Todd has more than 15 years of search experience in the same innovation-driven industry sectors asBSG. “I’m excited to have Todd join us to run the TalentBench brand,” said Clark Waterfall,BSG Managing Director. “Todd has been an industry colleague and friend for more than 15 years. The synergies run deep.”

Before joining TalentBench, Todd was Vice President of Sales and Marketing at Altela, the leading company in water treatment for the oil and gas industry, where he was responsible for identifying new business sectors and driving revenue in the U.S. and international markets. Prior to Altela, Todd was COO at CleanSwitch Solar, a photovoltaic engineering and integration company. He also raised venture capital financing for Talent Capital Group, an executive search firm that recruited leaders to drive the success of innovative companies in the technology and renewable sectors. Previously Todd built management teams for both Idealab, a creator and operator of technology companies, and the Yankee Group, the global technology market research firm.

 

Todd serves on the board of directors of Coronado Ventures Forum, an organization focused on educating and connecting entrepreneurs with private equity financing. He is a graduate of Pennsylvania State University and attended the Babson MBA program. “TalentBench expands our recruiting services,” said Todd, “and helps emerging technology companies who want the quality of an executive-level retained search for their key individual contributor through to their Vice President-level roles.”

 

CEO Search | Robots that automate $8B+ problem

BSG Team Ventures is excited to be engaged on the CEO search for an emerging, venture- backed robotics company that develops and sells automation systems into an $8B+ market where tasks are currently executed entirely via manual labor.   The first product is in beta and moving toward commercial launch September of this year.

The current co-founder & CEO has successfully taken the company from concept through design & beta launch.  He’s driving the search for his replacement as they enter their next stage of growth to maximize the company potential they’ve built up over the last 3+ years of research, development and customer learning.  He’ll step into the co-pilot role with the new CEO driving commercial adoption, sales expansion, and next generation product roadmap.

The company is looking for a strong sales, marketing & strategy savvy builder-leader to step in and take over the pilot role.

________

COMPANY HIGHLIGHTS


  • ONE OF MOST EXCITING NEW INNOVATION FRONTIERS Robotics/automation
  • DEEP ENGINEERING BENCH with  founding team members responsible for the initial success and IPO of iRobot
  • LARGE ADDRESSABLE TARGET MARKET–$2.5B for first product, $8B+ market for planned 2nd generation products, automating an otherwise manual-labor intensive industry with a first to market solution
  • READYING FOR COMMERCIAL LAUNCH NOW with growing backlog for commercial units driven from successful field beta trials over the last 6+ months
  • WELL-FUNDED with 9-12 months of runway

________

THE CEO NEED

As CEO, we’re looking for the following 4 prior experiences as a builder-leader:

• Success in companies that integrate hardware, software, and electromechanics

• P&L leadership of  a direct sales-driven and field services intensive organization selling into a large global customer base

• Strong grow-it/scale-it-stage experience, having grown companies or divisions from new product launch to $25M or more in revenues

• Prior track record of recruiting and motivating A-caliber teams

Companies that might be part of this executive’s career progress cover a broad spectrum of industries sectors, including industrial automation, light vehicle developers, medical devices, aerospace & military technologies, or mission critical hardware/software systems.

The following bubble diagram frames the key success attributes critical to the role—

For more information, contact Clark Waterfall, Managing Director.

2nd Annual Cooley Medical Device Growth Conference – Boston, November 9, 2011

We’re pleased to partner with Cooley LLP, Ernst & Young & BMO Capital Markets to put on this invitation-only conference.  Below is an agenda overview and speaker highlights.

If interested, please email clark [at] bsgtv.com.

WEDNESDAY, NOVEMBER 9, 2011 |  12:00 noon – 7:00 pm

Mandarin Oriental, Boston 776 Boylston Street  |  Boston, Massachusetts

Cooley LLP, Ernst & Young LLP and BMO Capital Markets invite you to an exclusive gathering of leading executives, investors, entrepreneurs and thought leaders in the medical device industry for the second annual Cooley Medical Device Growth Conference in Boston. This event will focus on the key drivers affecting the medical device industry and explore growth strategies for medical device companies.

KEYNOTE SPEAKER

Dr. Michael J. CimaProfessor of Materials Science and Engineering, Massachusetts Institute of Technology

TOPICS TO BE DISCUSSED [ view full agenda ]

  • Pulse of the Industry: Medical Technology Report 2011 – Ernst & Young’s annual report on the medical device industry
  • Developing and Implementing a Sales & Marketing Strategy -  Keys to achieving growth and ensuring regulatory compliance
  • An Open Discussion with Thought Leaders – A fireside chat with CEOs at revenue stage medical device companies on the medtech industry, opportunities and challenges, lessons-learned, etc.
  • What’s Getting Done? A discussion of trends in IPOs, M&A deals and strategic collaborations

REGISTRATION REQUIRED. This event is by invitation only. Registration is limited to representatives of medical device companies and investors, and is subject to approval.

PANELISTS AND MODERATORS INCLUDE

  • Joseph ArmyGeneral Manager, Medtronic Advanced Energy (Formerly President and Chief Executive Officer, Salient Surgical Technologies)
  • Michael CimaProfessor of Materials Science and Engineering, Massachusetts Institute of Technology
  • Kevin CaseyPartner, Ernst & Young LLP
  • Drew GanttPartner, Cooley LLP
  • Ron GoldmanChief Executive Officer, Accuvein
  • Larry KnopfSenior Vice President and General Counsel, HeartWare, Inc.
  • Michael McGrailAttorney, Cooley LLP
  • Yiannis MonovoukasChairman, President and Chief Executive Officer, TEI Biosciences Inc.
  • Michael NeubergerManaging Director and Head of Healthcare Group, BMO Capital Markets
  • Stu RandlePresident and Chief Executive Officer, GI Dynamics
  • Charles SherwoodPresident and Chief Executive Officer, Anika Therapeutics, Inc.
  • Mark SpeersPartner and Managing Director, Health Advances
  • Peter StebbinsVice President, New Business Development, DePuy Mitek and Codman, J&J Family of Companies
  • Kevin SeifertChief Executive Officer, Facet Technologies, Inc.
  • Don SternPartner, Cooley LLP (Former US Attorney)
  • Mark WeeksPartner, Cooley LLP
  • Robert WhitePresident & Chief Executive Officer, TyRx, Inc.

CEO Survey, Fall 2011 | Questions

How & What Growth-stage CEOs Are Ending 2011 & Planning for 2012

Below is the hyperlink to take the Q4 CEO peers speed-survey, exclusively for growth-stage CEOs. This survey focuses on “How & What Growth-stage CEOs are Ending 2011 & Planning for 2012″

This shouldn’t take more than 5 minutes of a busy CEO’s time–

We here at BSG Team Ventures periodically take the temperature of the markets we serve. The survey is no more than 15 questions, most simple multiple-choice.

These surveys are created and compiled by BSG Team Ventures as a courtesy to our executive ecosystem with the belief that knowledge is power. Aggregated peer-provided knowledge is “actionable power.”

To compare how you’re feeling a year later with the survey results from Q4 2010, titled “CEOs Plan for 2011”, go to http://www.bostonsearchgroup.com/blog/q4-2010-ceo-survey-of-growth-stage-companies/

We make an effort to survey only those who fit the category (in this case, sitting CEOs or board member/founders of technology/science-driven growth-stage companies). [Note, if you don't fit the aforementioned description, please refrain from responding.]

Feel free to forward to the qualified CEOs in your sphere of influence. The more data generated, the more accurate the trend lines.

All responses are anonymous due to the web-based survey technology employed.

We will forward the survey results within the next two weeks to the email address on file. Please let us know if there is another email address you wish us to send the results to as well.

CEO search, break-through medical devices for wound closure

BSG Team Ventures has been retained to bring aboard the new CEO for a break-through approach to wound closure.  The company has a patent portfolio and 4 products, two already with FDA approval, and a new Series B round of funding from passionate venture capital partners.

The addressable market is more than $5 Billion, and includes applications for plastic and reconstructive surgery, biopsy, military, perinatal, laproscopic, and other orthopedic surgical procedures.

The company is currently located in the San Francisco Bay area, California, having been founded in 2007.

Highlights of the new CEO’s track record and experience will include the following:

  • Strong commercialization stage leadership experience, with a focus on establishment of both direct and channel sales distribution
  • Experience with oversight of manufacturing and clinical trials for 510K regulatory approvals
  • Executive team-building, with particular emphasis on the sales, marketing, business development, manufacturing, and operations side
  • Corporate Development expertise in developing key strategic partnerships across the medical consumables/disposables ecosystem
  • Experience taking companies from pre-revenue to $50+M in revenues
  • For a more detailed outline of key success attributes, see the Venn diagram below.

    For more information regarding this search, please email clark [at] bsgtv-dot-com.

    Sales Leadership Searches for Fast Growing Medical Clinical Software Provider

    The Company

    Our client provides education solutions software for risk management and patient safety.   It has strategic partnerships with Risk Management Foundation of the Harvard Medical Institutions; and Hospital Corporation of America. Our Clients customers deploying its e-learning content represent a who’s-who of nationally recognized hospital systems and medical malpractice insurers.

    The Position

    The Vice President of Sales for the eLearning product suite will report to the CEO, and be responsible for all revenue generating activities within the group.

    Essential Responsibilities

  • Individual sales responsibility (player-coach role)
  • Divisional revenue ownership
  • Sales team-building
  • Sales leadership and sales pipeline management
  • Developing and managing detailed budgeting & forecasting
  • Developing sales and distribution plan
  • Developing partnerships in upstream indirect sales channels
  • Ideal Candidate Profile

    The diagram below illustrates the intersection of competencies critical in the VP Sales position:

    Staff & Team

    The company currently employs 35 full time staff and a large pool of contractors involved in product development.  As the company evolves their focus to place greater emphasis on the larger accounts, this team will evolve.  Historically the sales team has reported to the CEO, with the addition last year of a Director of Sales.  In the future, the VP of Sales will report to the CEO and the full sales team will report to the VP.  The VP Sales will have a team of both inside and outside sales, currently comprised of 6.

    Financial Backing

    The company is a privately held, profitable company with significant growth over the preceding two years.  As part of their growth strategy, the company took private equity capital in 2009.  Future growth will be funded by a combination of cash flow generated from retained earnings, prior external equity capital, and potential additional equity capital as deemed attractive by current company stakeholders and leadership.

    Compensation

    Compensation is competitive with the position’s requirements.  In a performance-based environment, this will include base salary and incentive bonus structure based on both individual, department, and corporate qualitative and quantitative MBOs.

    CEOs & VCs gather to talk about “new normals” as they face 2011

     

    “]
    Rob Day, Black Coral Capital | Michael Balmuth, Edison Ventures | Alexis Borisy, Third Rock Ventures

    Once or twice a year we as a firm gather CEOs from the Boston innovation ecosystem to share thoughts amongst themselves.  Often, the format is lubricated by a panel to kick things off.  Always, the format is lubricated by an open bar and dinner.

     This Fall’s CEO gathering in early November brought together 50 or so CEOs around the topic of planning for 2011, and what to expect as a CEO. 

    Whether early-stage venture, or mid-stage growth, investors are adopting a different approach to what they are looking for, how much they are putting to work, and what they expect to see as an end result.  This is proving true not just in the tech sector, but cleantech, medical device, and biotech.

     If CEOs are looking for more investment, whether growth equity, seed capital, or something in between, what are the “new normals” to think about going into 2011.  And if CEOs aren’t looking for money, but looking for exits, what are the expectations of investors in 2011 and beyond? 

     We assembled a panel of venture capital investors who all had raised new funds in the last year or so.  These investors also represented a different flavor than traditional venture capital.

     On the panel? 

    • Michael Balmuth, General Partner, Edison Venture Fund
    • Alexis Borisy, Partner, Third Rock Ventures
    • Rob Day, Partner, Black Coral Capital

     What were the “new normals” CEOs and VCs talked about?

     Here are a few that got some air time:

    2011 is likely to be an economic “ground hog year.”  The current economic cycle of “flat is the new up” is here to stay for the medium term;  In taking a flash vote of the room, the overwhelming majority felt that the economic conditions in which companies are being created are not going to change for the better any time soon.  Simply turning the calendar over from 2010 to 2011 is not likely to yield a more fertile or forgiving economic climate in which to grow innovation-stage companies.  In our recent survey  of growth-stage CEOsfor Q4 2010, we noted in a prior blog post that the vast majority of CEOs had already shifted their strategies or were planning to in the near future as a direct result of an expectation that 2011 might look a lot more like the end of 2009 or 2010 than ’07 [see CEO survey pie chart below]

     

    Seed rounds are becoming pervasive compared to prior quarters.  And these aren’t for Web 2.0 companies only.  CB Insights in their Q3 2010 summary demonstrated that this is a trend that is occurring in cleantech / greentech as well as healthcare IT.  All 3 investors on the panel agreed that seed funding makes sense.  Alexis Borisy, Partner at Third Rock Ventures, talked about their approach to seeding, saying that they tend to help start the companies, not just fund them, often taking an interim role on the executive team to incubate to a point of value inflection.  Michael Balmuth mentioned that although Edison Ventures doesn’t do “seed stage investing” per se, he loves to see companies that get seed rounds, as it often is an effort to drive toward profitability faster.  At that point, Edison may be more interested in a seed-funded company that achieves an early positive cash flow position than a typical heavily syndicated, multi-series venture-backed portfolio company.  Black Coral’s Rob Day added that he felt that investing in capital-efficient companies, even in the cleantech sector, was something he has advocated for a long time.  [see CB Insights graph of growth in seed round funding over last 5 trailing quarters, 2009-2010]

    • As an asset class, venture funds have lost money for a while now.  Limited partner investors in venture capital and even private equity believe that they still have to invest in this asset class because it does make money during economic or industry sector bubble periods, and to invest once a bubble has been established would mean missing the upside.  During other times, LPs try their best to pick the funds that outperform their peers.

     

    • Using investment banks to raise equity capital  should be done selectively.  If the industry is a small one, and the network is well established (like biotech investing Alexis pointed out), using an i-bank at an early stage is not the best idea.  However, in the cleantech sector where there are more total number of investors, they are internationally distributed, the industry is younger and less well-networked, and there is an imbalance in demand-supply (more money chasing fewer good deals), the investment banking solution may be just the right one.  One CEO, Larry Letteney of Second Wind in the cleantech sector, shared just such a recent positive experience in going out for their next round. 

     

    • Seek out funds that have real capital to invest, preferably “fresh.”  Each of the three funds represented on the panel had all raised funds in the last twelve months or so.  But there are a lot of funds that are at the end of their last fund.  Many are unlikely to raise another fund.  Many investors are taking meetings, but setting the bar exceedingly high because they have only an investment or two left, and they don’t want to get caught making a bad one given the challenge in delivering returns to LPs in the most recent investing vintages.  There was also a “beware” comment about funds who are making seed round investments at the end of their funds.  They are more likely to do so, as it is an easier story to message an investment mulligan to LPs if you can just say, “It was just a small seed investment, so no biggie.”  Caution was also expressed that an investor at the end of a fund making a seed investment will be less likely to have additional capital to invest even if the company is doing well.

    We hope to post a video snippet of the the VC-CEO dialogue for a flavor of the evening’s conversation in the near future.

    Q4 2010 CEO Survey of Growth-stage Companies | CEOs plan for 2011

    Each quarter we survey growth stage CEOs who are running innovation driven companies.  This quarter,  we had more than 60 CEOs responding.  CEOs were running companies in broadly defined technology (software, hardware, semiconductor, telecom), Internet (e-commerce, media, social, entertainment), medical devices, biotech, and cleantech / renewable energy sectors.

    A note on methodology.  We send these surveys only to those who fit the category (in this case, sitting CEOs or board member/founders of technology/science-driven growth-stage companies).    All responses were anonymous due to the web-based survey technology employed. The majority of respondents were in the United States, with the highest concentration on the East and West coasts (New York, Boston, and San Francisco/Silicon Valley areas).

    For prior survey results from Q2 2010, titled “Impact of Economy and Renewed Growth”, go to http://www.bostonsearchgroup.com/blog/ceo-survey-results-q2-2010-%e2%80%93-impact-of-economy-renewed-growth/ .

    ECONOMIC CLIMATE

    The first set of questions was around the economic conditions in which each CEO felt s/he was operating.    One question we continue to ask and re-ask over the last six quarters or so targets the turbulence in the macro- economic climate.  It is interesting to compare CEO responses to the same question, “Do you anticipate a double dip in the near term future?”

    * In Q3 2009, more than half  (54%) of CEOs polled were expecting a double dip, and planning accordingly

    * In our Q2 2010 survey,  again 50% felt a second economic correction was likely, the biggest percentage of those CEOs believing it would be in either Q3 2010 or sometime in 2011.  The other half  of CEOs felt the specter of recession was behind them

    * Currently in Q4 CEOs were consistent with prior quarters with a bit more than 50% indicating they didn’t feel a double dip was likely, and the other half of the CEOs saying either a 50/50 probability or greater (16% feeling more likely than not)

    So less than 1 in 5 CEOs feel another economic dip is likely.  No CEOs selected the ” greater than 75%” probability.

    It’s interesting to do a meta graph of the changing CEO sentiment on this question.  Surprisingly, the graph would be sloping downward, but not as much as many would hope.  The high point was certainly back in Q3 2009, but even throughout 2010, as many CEOs were fearful of a negative correction as those who felt it was behind us.  No doubt this “lack of confidence” index doesn’t inspire the CEO with a swashbuckling, damn-the-torpedoes-full-speed-ahead attitude toward growing their companies.  Rather, it makes CEOs think in short-term windows, perhaps 3 months at a time, with little appetite to make medium or long-term bets.

    Those CEOs who felt another downturn was likey referenced several factors that might tip the scales negative–  gridlock in Congress due to midterm elections and likelihood that Democrats lose congressional majority, a belief that a bad Q4 holiday retail shopping was likely, and the persistent overhang of ongoing commercial and residential loan defaults.

    As for when another economic dip might occur if it were to occur, the vast majority of CEOs pointed to Q1, 2011, with Q4 of this year and Q2 2011 tying for second at 18% each.

    STRATEGY

    Almost 50% of CEOs polled said that they had either made a shift in strategy in 2010, or were planning to in the near future.  Granted, growth-stage companies are prone to shifting strategy until they land upon the best formula for significant and sustainable growth.  However ~50% is a big number, and clearly a chunk of those companies have been driven to rethink their strategies because of the challenging economic climate, the concern over the future, and the possibility that 2010 might represent “the new normal” where with no economic “rising tide” no help generated to float all company boats as in periods of economic expansion in the past (1997-2000, 2005-2008, etc).

    CASH FLOW

    The majority of CEO survey respondents (49%) indicated that they were still planning on burning cash over the next 2 quarters.  24% indicated they would be profitable.  CEO comments regarding this question indicated an overwhelming drive toward cash flow break even.  That was the big push and focus for their companies in 2010, and if they hadn’t achieved it yet, they were gunning to by end of the first quarter of 2011.  CEOs also commented that they were trying to run their companies at break even, with any extra EBIT being reinvested back into the company for additional growth.

    COST REDUCTION PLANS

    When asked what were the top 3 areas CEOs were targeting for cost reduction, the following table summarizes their responses, representing a combination of spend reduction and staff reduction in non-core areas.  There was a preference by CEOs to favor non-staff cuts over cutting headcount if at all possible, but many acknowledged that in order to make meaningful cuts, staff had  to be considered in the equation.

    CEO responses when asked about increasesin spend were logical.  The top three in order were sales, marketing, and R&D.  Many of the comments about this question noted the fact that outside of directly growing revenues, additional spend was hard to build in when many CEOs are driving toward a minimum cash-neutral mandate and economic uncertainties are driving CEOs to think conservatively rather than expansively.

    [Click on "more" below for remaining 8 slides and narrative from Q4 2010 CEO survey]

    More…

    CEO Survey, Fall 2010

    TOPIC: How & What Growth-stage CEOs Are Planning for 2011

    Below is the hyperlink to take the Q4 CEO peers speed-survey, exclusively for growth-stage CEOs.  This survey focuses on “How & What Growth-stage CEOs are Planning for 2011″

    This shouldn’t take more than 5 minutes of a busy CEO’s time–

    We here at BSG Team Ventures periodically take the temperature of the markets we serve. The survey is no more than 15 questions, most simple multiple-choice.

    These surveys are created and compiled by BSG Team Ventures as a courtesy to our executive ecosystem with the belief that knowledge is power.  Aggregated peer-provided knowledge is “actionable power.”

    For the survey results from Q2 2010, titled “Impact of Economy & Renewed Growth Planning”, go to http://www.bostonsearchgroup.com/blog/ceo-survey-results-q2-2010-%E2%80%93-impact-of-economy-renewed-growth/

    We make an effort to survey only those who fit the category (in this case, sitting CEOs or board member/founders of technology/science-driven growth-stage companies). [Note, if you don't fit the aforementioned description, please refrain from responding.]

    Feel free to forward to the qualified CEOs in your sphere of influence. The more data generated, the more accurate the trend lines.

    All responses are anonymous due to the web-based survey technology employed.

    We will forward the survey results within the next two weeks to the email address on file. Please let us know if there is another email address you wish us to send the results to as well.

    « Older Posts